This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Ancrod in acute stroke

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ancrod converts fibrinogen into soluble fibrin products, there by decreasing serum fibrinogen and reducing its use in thrombus formation.

In a trial of 500 patients, randomised to receive either Ancrod or placebo within 3 hours, 42% of patients given Ancrod had a total or near-total recovery compared to 34% in the placebo group.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.